PHP
PACB icon

Parkman Healthcare Partners’s Pacific Biosciences PACB Stock Holding History

Parkman Healthcare Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-210,580
Closed -$1.76M – 102
2023
Q3 		$1.76M Sell
210,580
-114,920
-35% -$1.31M 0.32% 79
2023
Q2 		$4.33M Buy
+325,500
New +$3.96M 0.75% 41

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Parkman Healthcare Partners's PACB Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 210,580 shares — an estimated $1.76M sold.

Parkman Healthcare Partners first reported a position in PACB in Q2 2023 and held it in 2 quarters. The position peaked at $4.33M in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Parkman Healthcare Partners reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 210,580 Pacific Biosciences shares in Q4 2023, an estimated $1.76M.
  • Parkman Healthcare Partners first reported a position in Pacific Biosciences in Q2 2023 and held it in 2 quarters.
  • Parkman Healthcare Partners's Pacific Biosciences position peaked at $4.33M in Q2 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.